Therapeutic strategies for diabetic cardiomyopathy: SGLT-2 inhibitors, GLP-1 receptor agonists, and beyond
Year: 2025
Type: article
Abstract: Diabetic cardiomyopathy (DCM) is defined as the presence of myocardial injury in patients with diabetes mellitus (DM) without other cardiac conditions such as ischemic heart disease or hypertensive heart disease [1].DCM is a major complication of DM and a prominent cause of heart failure (HF) [2].Although the management of DCM has not yet been specifically established, medications such as some sodium-glucose cotransporter
Source: Kardiologia Polska
Institutions: Instituto de Salud Carlos III, Centro de Investigación en Red en Enfermedades Cardiovasculares, Hospital Regional Universitario de Málaga, Centro de Investigación Biomédica en Red, Instituto de Investigación Biomédica de Málaga, Universidad de Málaga, Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4411133476